Response to: “A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post hoc results from the certolizumab pegol phase 4 PREDICT trial”

Detalles Bibliográficos
Autores principales: Madison, Annelise, Andersen, Barbara L., Ajam, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381628/
https://www.ncbi.nlm.nih.gov/pubmed/30786929
http://dx.doi.org/10.1186/s13075-019-1848-4
_version_ 1783396536054448128
author Madison, Annelise
Andersen, Barbara L.
Ajam, Ali
author_facet Madison, Annelise
Andersen, Barbara L.
Ajam, Ali
author_sort Madison, Annelise
collection PubMed
description
format Online
Article
Text
id pubmed-6381628
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63816282019-02-28 Response to: “A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post hoc results from the certolizumab pegol phase 4 PREDICT trial” Madison, Annelise Andersen, Barbara L. Ajam, Ali Arthritis Res Ther Letter BioMed Central 2019-02-20 2019 /pmc/articles/PMC6381628/ /pubmed/30786929 http://dx.doi.org/10.1186/s13075-019-1848-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Letter
Madison, Annelise
Andersen, Barbara L.
Ajam, Ali
Response to: “A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post hoc results from the certolizumab pegol phase 4 PREDICT trial”
title Response to: “A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post hoc results from the certolizumab pegol phase 4 PREDICT trial”
title_full Response to: “A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post hoc results from the certolizumab pegol phase 4 PREDICT trial”
title_fullStr Response to: “A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post hoc results from the certolizumab pegol phase 4 PREDICT trial”
title_full_unstemmed Response to: “A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post hoc results from the certolizumab pegol phase 4 PREDICT trial”
title_short Response to: “A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post hoc results from the certolizumab pegol phase 4 PREDICT trial”
title_sort response to: “a somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post hoc results from the certolizumab pegol phase 4 predict trial”
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381628/
https://www.ncbi.nlm.nih.gov/pubmed/30786929
http://dx.doi.org/10.1186/s13075-019-1848-4
work_keys_str_mv AT madisonannelise responsetoasomatizationcomorbidityphenotypeimpactsresponsetotherapyinrheumatoidarthritisposthocresultsfromthecertolizumabpegolphase4predicttrial
AT andersenbarbaral responsetoasomatizationcomorbidityphenotypeimpactsresponsetotherapyinrheumatoidarthritisposthocresultsfromthecertolizumabpegolphase4predicttrial
AT ajamali responsetoasomatizationcomorbidityphenotypeimpactsresponsetotherapyinrheumatoidarthritisposthocresultsfromthecertolizumabpegolphase4predicttrial

Ejemplares similares